The FDA’s DDMAC issued a warning letter to AstraZeneca asserting that a company sales rep recommended or suggested to a healthcare professional an off-label use for Seroquel and Seroquel XR. The ...

UPDATE: An early victory for AstraZeneca. A Florida judge just dismissed the first two cases on motions for summary judgment. So, er ... never mind! Next week in Orlando federal court the first of ...

Drugmaker AstraZeneca recently settled a lawsuit with the state of Kentucky over allegations of improperly marketing its atypical antipsychotic drug Seroquel. Under the settlement, the London-based ...

Was AstraZeneca touting Seroquel for off-label uses? Or was it simply plotting to get FDA approval for new indications for the atypical antipsychotic? These are the essential questions posed by a mega ...

AstraZeneca's ($AZN) battle over Seroquel marketing missteps drags on. Texas Attorney General Greg Abbott has sued the company for fraud, saying that AstraZeneca ...

BNET noted recently that AstraZeneca seemed to be winning the war over whether its antipsychotic Seroquel causes weight gain and diabetes. The company reported that of 10,000 cases none had gotten to ...